260254-74-8

Basic information

• Product Name: (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine
• Synonyms: (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine
• CAS NO: 260254-74-8
• Molecular Formula: C₁₅H₂₄N₂
• Molecular Weight: 232.36446
• Mol File: 260254-74-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine(260254-74-8)
• EPA Substance Registry System: (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine(260254-74-8)

Safety Data

• Hazardous Substances Data: 260254-74-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and potential biological activities make it a valuable candidate for the development of new drugs targeting a range of medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine is employed as a building block for the design and synthesis of novel compounds with potential therapeutic applications. Its structural features can be modified to optimize the pharmacological properties of the resulting compounds.
Used in Drug Discovery:
(2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine is utilized in drug discovery processes as a starting point for the identification of new lead compounds. Its unique chemical properties and potential interactions with biological targets make it a promising candidate for the development of innovative therapeutic agents.
Used in the Treatment of Medical Conditions:
While further research is required to fully understand the pharmacological properties of (2R,5S)-1-Benzyl-5-Isopropyl-2-Methyl-Piperazine, it may have potential applications in the treatment of various medical conditions. Its biological activities could be harnessed to develop new therapies for a range of diseases and disorders.

Upstream product

• 260254-70-4 N-α-(9-fluorenylmethoxycarbonyl)-L-valinyl-N-β-benzyl-L-alanine methyl ester 
• 103321-53-5 (S)-(9H-fluoren-9-yl)methyl 1-chloro-3-methyl-1-oxobutan-2-ylcarbamate 
• 68858-20-8 Fmoc-Val-OH 
• 260254-72-6 (3S,6R)-1-Benzyl-3-isopropyl-6-methyl-piperazine-2,5-dione 

Relevant articles and documents

Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase

N'-Methyl-N-(4-tert-butyl-1,2,5,6-tetrahydropyridine)thiourea, SDZ048- 619 (1), is a modest inhibitor (IC50 = 180 μM) of pyruvate dehydrogenase kinase (PDHK). In an optimization of the N-methylcarbothioamide moiety of 1, it was discovered that amides with a small acyl group, in particular appropriately substituted amides of (R)-3,3,3-trifluoro-2-hydroxy-2- methylpropionic acid, are inhibitors of PDHK. Utilizing this acyl moiety, herein is reported the rationale leading to the optimization of a series of acylated piperazine derivatives. Methyl substitution of the piperazine at the 2- and 5-positions (with S and R absolute stereochemistry) markedly increased the potency of the lead compound (> 1000-fold). Oral bioavailability of the compounds in this series is good and is optimal (as measured by AUC) when the 4-position of the piperazine is substituted with an electron-poor benzoyl moiety. (+)-1-N-[2,5-(S,R)-Dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (14e) inhibits PDHK in the primary enzymatic assay with an IC50 of 16 ± 2 nM, enhances the oxidation of [14C]lactate into 14CO2 in human fibroblasts with an EC50 of 57 ± 13 nM, diminishes lactate significantly 2.5 h post-oral-dose at doses as low as 1 μmol/kg, and increases the ex vivo activity of PDH in muscle, liver, and fat tissues in normal Sprague-Dawley rats. These PDHK inhibitors, however, do not lower glucose in diabetic animal models.